TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01706939

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Reduced Dose Radiation
Description: Reduced Dose Radiation (5600 cGy) dose radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dose Radiation
Description: Standard Dose Radiation (7000 cGy) dose radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Day 1, every 7 days ( + 2 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Day 1, every 7 days ( + 2 days)
Study: NCT00395707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: 0.3mg/0.05 ml or 0.5mg/0.05 ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: 0.3mg/0.05 ml or 0.5mg/0.05 ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab (Lucentis)
Description: 0.3mg/0.05 ml intravitreally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab (Lucentis)
Description: 0.5mg/0.05 ml
Study: NCT00374543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: Ziprasidone, flexibly dosed from 40 to 160 mg/day, for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered daily for 8 weeks
Study: NCT01740856

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rest three hours
Description: Intervention group (IG), will maintain bed rest supine for two hours after the digital compression. After this period prescribed, patients sit in bed with the head elevated at 45 degrees for 50 minutes and then walk within the unit hemodynamic for about 10 minutes. Afterwards patients remain sitting out of bed in hemodynamics unit, until they are five hours, then they will be discharge.
Study: NCT02835222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO
Study: NCT00045110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: correlative studies
Study: NCT01923155

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Study: NCT02283931

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TTE / NICOM

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TTE / NICOM

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TTE / NICOM
Study: NCT03411967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: apatinib mesylate tablets 500mg, po, qd, continued until the next cycle, taking on an empty stomach (daily taken at the same time), every 3 weeks For one cycle, a total of 4 to 6 cycles of treatment, apatinib has been taken until the disease progresses, intolerable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel, 60 mg / m2, d1, iv ,every 3 weeks For one cycle, a total of 4 to 6 cycles of treatment
Study: NCT01740856

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rest five hours
Description: Control group (CG) maintain bed rest supine for four hours after the digital compression. After this period, the patients sit in bed with the head elevated at 45 degrees for 50 minutes and then walk into the unit hemodynamic for 10 minutes. After that patients receive discharge.
Study: NCT03682718

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcervical Foley catheter
Description: combined methods of induction of labor Floey Catheter with misoprstol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprstol inserted vaginally for induction of labor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Misoprstol inserted vaginally for induction of labor
Study: NCT00126438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 123I-mIBG (meta-iodobenzylguanidine)
Description: Single Dose
Study: NCT03093545

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Equine Rabies Immunoglobulin
Description: 40 IU per kg of body weight of ERIG at Day 0
Study: NCT02575885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette
Description: Receive different type of ENDS product at each visit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette
Description: Receive BLU e-cigarette ENDS product
Study: NCT03093545

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Equine Rabies Immunoglobulin
Description: 40 IU per kg of body weight of ERIG at Day 0

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Purified chick-embryo cell rabies vaccine
Description: 1 ml of PCEC Rabies vaccine on days 0, 3, 7, 14 and 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Purified chick-embryo cell rabies vaccine
Description: 1 ml of PCEC Rabies vaccine on days 0, 3, 7, 14 and 28.
Study: NCT03453359

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIS monitor
Description: The investigators will place on the forehead of all patients the sensor BIS quatroTM, that connects with this monitor, and they will guide sedation and will record the values obtained.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ramsay scale
Description: In this group, sedation is guided by the Ramsay monitoring scale. The investigators will talk with the patients and will determine the corresponding level of sedation.
Study: NCT02660385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: This behavioral intervention includes strategies for modifying thoughts, cognitions and behaviors regarding sleep provided by a therapist in a group format.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Management Education for Heart Failure
Description: This is an educational education designed to teach patients about self-management their heart failure. It includes information on medications, lifestyle, cardiac devices, diet, and when to seek assistance from a health care provider.
Study: NCT01173159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omegaven
Description: For the first two days of treatment, subjects will receive Omegaven® at 0.5 g/kg per day to assess tolerance and will progress to a maintenance dosage of up to 1g/kg per day over 12 hours at an infusion rate of 1 g/kg/12 hours (10 ml/kg/12 hours). Dosing is based on previously described dosing of fish-oil emulsions as monotherapy noted within the literature. Omegaven® will be infused intravenously through either a central or peripheral catheter in conjunction with other parenteral nutrition containing dextrose and amino acids. Omegaven® is isotonic. It is compatible with parenteral nutrition solutions and may be co-infused via y-site.
Study: NCT01280799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance-based separated family treatment
Description: Family treatment that combines Acceptance and Commitment Therapy (ACT) for the adolescent with Parent Skills Training for caregivers. The treatment package is designed to increase willingness to experience difficult thoughts, feelings, and bodily sensations in order to engage in effective behavior. To facilitate this, caregivers are provided with psychoeducation on eating disorders and skills in behavior management, self-regulation, and emotion regulation.
Study: NCT01199432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU（intravenous infusion）+epirubicin+cyclophosphamide
Description: 5-FU 200mg/m2 per day from day 1 to day 28 （Continuous intravenous infusion）; epirubicin 65mg/m2 per day on day 1 and day 8 and cyclophosphamide 500mg/m2 per day on day 1 and day 8 ; every 28 days as a cycle. Total four cycles is needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU（intravenous bolus）+epirubicin+cyclophosphamide
Description: 5-FU 500mg/m2 per day on day 1 and day 8（intravenous bolus）; epirubicin 65mg /m2 per day on day 1 and day 8 and cyclophosphamide 500mg/m2 per day on day 1 and day 8 ; every 28 days as a cycle. Total four cycles is needed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin+cyclophosphamide
Description: epirubicin 65mg/m2 per day on day 1 and day 8 and cyclophosphamide 500mg/m2 per day on day 1 and day 8 ; every 28 days as a cycle. Total four cycles is needed.
Study: NCT02558426

Intervention type: PROCEDURE
Intervention: Venous Surgery
Description: Patients with Varicose Veins will undergo to venous surgery procedure. Samples obtained from patients undergoing surgical removal of varicose veins will be collected and immediately preserved at -80°. Briefly, the venous tissueswill be excised, homogenized with a motor-driven homogenizer and total RNA will be isolated using the Trizol reagent (Invitrogen, Milan, Italy), according to the manufacturer's instructions. The expression of ERα, ERβ and GPER will be quantified by real-time PCR using the Step OneTM sequence detection system (Applied Biosystems Inc., Milan, Italy), following the manufacturer's instructions
Study: NCT01179633

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OPLON active patch

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham patch
Study: NCT01252433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy density feeding study
Description: In a crossover study, children are served all foods 1 day a week for 3 weeks. Meal entrees will vary in energy density (100%, 85%, 75%).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy density feeding study
Description: In a crossover study, children are served all foods 1 day a week for 3 weeks. Meal entrees will vary in energy density (100%, 85%, 75%).
Study: NCT00578019

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IM Nailing
Description: Patients randomized to Arm 1, A will be treated with a retrograde intramedullary nailing of the femur fracture utilizing the Smith \& Nephew supracondylar nail.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LISS
Description: Group B patients will have their fracture stabilized with the LISS plates (Synthes \[USA\], Paoli, PA, USA).
Study: NCT03085966

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous immune cell therapy
Description: Luteinizing Hormone Releasing Hormone Agonists (LHRH-a) and Autologous dendritic cells (DC) and central memory T cells (Tcm cells)
Study: NCT00857090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS201
Description: Stage 1: OMS201 irrigation solution at 3X the base concentration during surgery~Stage 2: OMS201 irrigation solution up to 10X the base concentration during surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Stages 1-2: Vehicle irrigation solution during surgery
Study: NCT01483027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraSphere
Description: yttrium 90 microspheres
Study: NCT00636246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline/[S,S]-reboxetine
Description: Tablets, 50mg sertraline/2mg \[S,S\]-reboxetine for 3 days orally, followed by 100mg sertraline/4mg \[S,S\]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/4mg \[S,S\]-reboxetine for 5 and one half weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline/[S,S]-reboxetine
Description: Tablets, 50mg sertraline/2mg \[S,S\]-reboxetine for 3 days orally, followed by 100mg sertraline/4mg \[S,S\]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/6mg \[S,S\]-reboxetine for 5 and one half weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline
Description: Tablets, 50 mg/day orally for 3 days, followed by 100 mg/day orally for 4 and one half weeks, followed by 150 mg/day orally for 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline
Description: Tablets, 50 mg/day orally for 3 days, followed by 100 mg/day orally for 4 and one half weeks, followed by 150 mg/day orally for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline/[S,S]-reboxetine
Description: Tablets, 50mg sertraline/2mg \[S,S\]-reboxetine for 3 days orally, followed by 100mg sertraline/2mg \[S,S\]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/2mg \[S,S\]-reboxetine for 5 and one half weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, orally once per day for 8 weeks
Study: NCT02575885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01284465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and patient liaison combination
Description: Group education sessions with Patient liaison using ecological momentary assessment principles

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control group
Description: Group education sessions at baseline, 3 and 6 months
Study: NCT02390284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost
Description: Lower intraocular pressure (IOP) by increasing outflow of fluid from the eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Description: Lower intraocular pressure by increasing outflow of fluid from the eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost
Description: Lower intraocular pressure by increasing outflow of fluid from the eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol
Description: Lower intraocular pressure by decreasing production of fluid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dorzolamide
Description: Lowers intraocular pressure by decreasing intraocular fluid production

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide
Description: Lowers intraocular pressure by decreasing intraocular fluid production

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Lowers intraocular pressure by decreasing intraocular fluid production

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methazolamide
Description: Lowers intraocular pressure by decreasing intraocular fluid production
Study: NCT06692517

Intervention type: PROCEDURE
Intervention: Laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy
Study: NCT00636246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline/[S,S]-reboxetine
Description: Tablets, 50mg sertraline/2mg \[S,S\]-reboxetine orally for 3 days, followed by 100mg sertraline/2mg \[S,S\]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/2mg \[S,S\]-reboxetine for 5 and one half weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [S,S]-reboxetine monotherapy
Description: Tablets, 2 mg/day orally for 3 days, followed by 4 mg/day orally for 4 and one half weeks, followed by 6mg/day for 3 weeks
Study: NCT02400918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Mindfulness and Acceptance-based Workbook for Social Anxiety and Shyness (Fleming & Kocovski, 2013)
Description: An acceptance and commitment therapy-based self-help workbook for social anxiety and shyness. It includes an 8-week program.
Study: NCT04433182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Induction phase: 6 cycles of Copa-RB every 28 days according to the following schedule~* Copanlisib (Copa): 60 mg/day i.v. on days 1,8,15~* Rituximab (R): 375 mg/sqm i.v. day 1\*~* Bendamustine (B): 90 mg/sqm i.v. days 1-2\*~note: during cycle 1 rituximab can be administered on day 2: in this case bendamustine will be administered on days 2-3; in the case of a frail patient or a patient with high tumor burden copanlisib could be administered on day 1, rituximab on day 2 and bendamustine on days 3-4, at physician discretion.~Maintenance phase: patients who reach at least SD after induction will receive a maintenance with copanlisib in monotherapy according to the following schedule:~• Copanlisib: 60 mg/day i.v. on days 1 and 15 in 28-day cycles for 1 year
Study: NCT01955720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655075
Study: NCT01827800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eHealth weight loss intervention
Description: This trial involves a multi-level, systems-change weight loss intervention. At the provider level, we make it easier for PCPs to deliver weight loss counseling by embedding patient progress data and counseling recommendations in the electronic health record. At the patient level, we provide engaging self-monitoring interfaces, immediate tailored feedback, skills training, and evidence-based lifestyle counseling from trusted care providers.
Study: NCT02261519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaBen®
Description: 500 mg twice daily (1000 mg total)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg twice daily (0 mg total)
Study: NCT02251405

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One bag, stainless container

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: One bag, stainless container
Study: NCT04138537

Intervention type: OTHER
Group type: OTHER
Intervention: OB volume
Description: The mean OB volume was calculated in cubic millimeters and compared between the two groups.

Intervention type: OTHER
Group type: OTHER
Intervention: OB volume
Description: The mean OB volume was calculated in cubic millimeters and compared between the two groups.
Study: NCT01103141

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Micropuncture needle set
Description: Groin access for vascular intervention

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard gauge-18 needle set
Description: Groin access for vascular intervention
Study: NCT04194541

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutimed Sorbact Hydroactive B wound dressing
Description: Wound dressing applied and changed as needed.
Study: NCT04138537

Intervention type: OTHER
Group type: OTHER
Intervention: CCCRC test
Description: CCCRC test was done for olfactory function assessment and compared between the two groups.

Intervention type: OTHER
Group type: OTHER
Intervention: CCCRC test
Description: CCCRC test was done for olfactory function assessment and compared between the two groups.
Study: NCT03225209

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OPTIFAST
Description: OPTIFAST meal replacement includes shakes, bars and soups. These meal replacements will completely replace the subject's diet for the first 12 weeks of the study (baseline-week 12) followed by a gradual transition back to prepared meals over 6 weeks (week 13-18). Attempt will be made to reduce or eliminate Lantus and Metformin as long as glycemic control is maintained.
Study: NCT00150488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uracyst
Description: 2% weekly for 6 weeks, monthly for 4 months
Study: NCT04404764

Intervention type: DRUG
Intervention: Nusinersen Injectable Product
Description: The patient´s treatment is provided by SUS. The following dosage scheme of nurinersen is the one approved by ANVISA (Brazilian National Health Surveillance Agency): Nusinersen, 12 mg (5 mL) on days 0 (zero), 14 and 28. A fourth dose will be on day 63 with a maintenance dose once every 4 (four) months. The study will NOT have direct influence on the care received by patients. Data on adherence, interventions, hospitalizations, mechanical ventilation, procedures and adverse events will be obtained from the patients´ medical records.
Study: NCT02390921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fisiogen Ferro Forte
Description: The patients will interrupt the endovenous treatment with iron and will receive liposomated iron 28mg/daily during 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venofer
Description: The patients will continue their usual endovenous administration of Venofer 300mg every 3 month
Study: NCT03187418

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MicroPulse® P3 Glaucoma Device (MP3)
Description: Laser settings will be programmed as follows: power-2000mW-2500mW (average 2000mW) of 810nm infrared diode laser set on micropulse delivery mode; micropulse on time-0.5ms; micropulse off time-1.1ms; and duty cycle (proportion of each cycle during which the laser is on)-31.33 %.~The laser probe will be applied in a continuous sliding or painting motion from 9:30 to 2:30 and from 3:30 to 8:30. The probe will be applied perpendicular to the limbus with the edge directly on the limbus at all times (fiberoptic tip at 3 mm posterior to the limbus).~The laser will be delivered over 360° for 160-320s. Treatment duration will be adjusted based on iris color and glaucoma severity (mild glaucoma: 160s, moderate glaucoma: 240s, advanced glaucoma: 240-320s).
Study: NCT03177460

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMS Inhibitor JNJ-40346527
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Undergo radical prostatectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Undergo radical prostatectomy
Study: NCT02407925

Intervention type: BEHAVIORAL
Intervention: Feedback
Description: 3-monthly or no 3-monthly feedback on results of optical diagnosis
Study: NCT00083759

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: natalizumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo